OM:SEDANA

Stock Analysis Report

Executive Summary

Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally.


Snowflake Analysis

Excellent balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Sedana Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SEDANA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

27.9%

SEDANA

6.4%

SE Medical Equipment

0.3%

SE Market


1 Year Return

84.3%

SEDANA

12.6%

SE Medical Equipment

-13.2%

SE Market

Return vs Industry: SEDANA exceeded the Swedish Medical Equipment industry which returned 12.6% over the past year.

Return vs Market: SEDANA exceeded the Swedish Market which returned -13.2% over the past year.


Shareholder returns

SEDANAIndustryMarket
7 Day27.9%6.4%0.3%
30 Day33.9%-8.9%-19.3%
90 Day45.7%-12.5%-23.1%
1 Year84.3%84.3%14.5%12.6%-11.0%-13.2%
3 Yearn/a34.5%19.3%-0.2%-14.7%
5 Yearn/a27.5%5.1%6.0%-16.1%

Price Volatility Vs. Market

How volatile is Sedana Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sedana Medical undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SEDANA (SEK199) is trading below our estimate of fair value (SEK538.75)

Significantly Below Fair Value: SEDANA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SEDANA is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: SEDANA is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SEDANA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SEDANA is overvalued based on its PB Ratio (7.9x) compared to the SE Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Sedana Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

108.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SEDANA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: SEDANA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SEDANA's is expected to become profitable in the next 3 years.

Revenue vs Market: SEDANA's revenue (39.6% per year) is forecast to grow faster than the Swedish market (4.1% per year).

High Growth Revenue: SEDANA's revenue (39.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SEDANA's Return on Equity is forecast to be low in 3 years time (8.5%).


Next Steps

Past Performance

How has Sedana Medical performed over the past 5 years?

-72.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SEDANA is currently unprofitable.

Growing Profit Margin: SEDANA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SEDANA is unprofitable, and losses have increased over the past 5 years at a rate of -72.5% per year.

Accelerating Growth: Unable to compare SEDANA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SEDANA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.6%).


Return on Equity

High ROE: SEDANA has a negative Return on Equity (-2.56%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sedana Medical's financial position?


Financial Position Analysis

Short Term Liabilities: SEDANA's short term assets (SEK486.9M) exceed its short term liabilities (SEK23.9M).

Long Term Liabilities: SEDANA has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: SEDANA is debt free.

Reducing Debt: SEDANA had no debt 5 years ago.


Balance Sheet

Inventory Level: SEDANA has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if SEDANA's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SEDANA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SEDANA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Sedana Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SEDANA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SEDANA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SEDANA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SEDANA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SEDANA's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Christer Ahlberg (48yo)

3.17s

Tenure

Mr. Christer Ahlberg serves as the President and Chief Executive Officer of Sedana Medical AB (publ). He serves as CEO of Sedana Medical AB (publ) since February 01, 2017. Mr. Ahlberg has more than 10 year ...


CEO Compensation Analysis

Compensation vs Market: Christer's total compensation ($USD0.00) is below average for companies of similar size in the Swedish market ($USD653.62K).

Compensation vs Earnings: Insufficient data to compare Christer's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Christer Ahlberg
President & CEO3.17yrsno data0.88% SEK39.8m
Maria Engström
Chief Financial Officer3.17yrsno datano data
Robert Dorp
VP & Head of Salesno datano data0.49% SEK22.2m
Ron Farrell
VP and Head of R&D and Qualityno datano data2.78% SEK125.6m
Peter Sackey
Chief Medical Officer2.25yrsno data0.0043% SEK194.1k

3.2yrs

Average Tenure

48yo

Average Age

Experienced Management: SEDANA's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sten Gibeck
Independent Director15.25yrsno data5.41% SEK244.9m
Ola Magnusson
Director15.25yrsno data5.83% SEK263.7m
Thomas Eklund
Chairman of the Board6.25yrsno data1.83% SEK82.9m
Bengt Julander
Independent Director9.25yrsno datano data
Eva Walder
Director1.92yrsno data0.014% SEK636.6k

9.3yrs

Average Tenure

66yo

Average Age

Experienced Board: SEDANA's board of directors are considered experienced (9.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SEDANA insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.6%.


Top Shareholders

Company Information

Sedana Medical AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sedana Medical AB (publ)
  • Ticker: SEDANA
  • Exchange: OM
  • Founded: 2005
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: kr4.525b
  • Shares outstanding: 22.74m
  • Website: https://www.sedanamedical.com

Number of Employees


Location

  • Sedana Medical AB (publ)
  • Vendevägen 87
  • Danderyd
  • Stockholm County
  • 182 32
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SEDANAOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJun 2017
7D2DB (Deutsche Boerse AG)YesShare CapitalDEEURJun 2017

Biography

Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers AnaConDa and AnaConDa-S, which are disposable medical devices that enables the administration of volatile anesthetics; AnaConDa Syringe, a 50/60ml syringe; FlurAbsorb, a charcoal filter for removing halogenated hydrocarbon anesthetic gases, such as isoflurane or sevoflurane; FlurAbsorb accessory kit comprising lines and connectors for connecting the filter to the ventilator and gas monitor; and FlurAbsorb mount to hold the filter during scavenging of anesthetic gas. It also provides isoflurane/sevoflurane and Sevorane QuickFil filling adaptors; gas sampling lines to prevent anesthetic volatile agents from leaching through the wall of the tube; and Nafion lines to reduce the accumulation of condensate in the anesthetic gas measuring line and the water trap of the gas monitor. In addition, the company is developing IsoConDa, a therapy for inhalation sedation in intensive care. Sedana Medical AB (publ) was founded in 2005 and is headquartered in Danderyd, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/04 05:47
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.